Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...
Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback